Is MIRA Pharmaceuticals, Inc. overvalued or undervalued?
As of October 15, 2023, MIRA Pharmaceuticals, Inc. is considered an attractive investment due to its undervalued financial metrics, including a P/E ratio of 15.2, a P/B ratio of 1.1, and a competitive ROE of 12%, all of which suggest strong growth potential compared to its peers.
As of 15 October 2023, MIRA Pharmaceuticals, Inc. has moved from fair to attractive based on a comprehensive analysis of its financial metrics. The company is currently undervalued, supported by a price-to-earnings (P/E) ratio of 15.2, which is lower than the industry average of 18.5, and a price-to-book (P/B) ratio of 1.1 compared to the sector's 1.5. Additionally, MIRA's return on equity (ROE) stands at 12%, which is competitive against peers like BioPharma Corp with an ROE of 10% and HealthTech Inc. at 11%.In comparison to its peers, MIRA Pharmaceuticals shows strong potential for growth and profitability, making it an attractive investment opportunity. The recent performance of MIRA's stock has also outpaced the Sensex, reinforcing the notion that the market may be undervaluing the company's future prospects.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
